Extremity Perfusion for Sarcoma

Surgical Oncology Clinics of North America

Volumn 17, Issue 4, 2008, Pages 805-824

  Hoekstra, Harald Joan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; CAELIX; CARBOPLATIN; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; FLUORO 3' DEOXY 3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; INTERFERON; MELPHALAN; TASONERMIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANGIOGRAPHY; BLISTER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL EVALUATION; COMPARTMENTAL SYNDROME; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOXICITY; EDEMA; EPIDERMOLYSIS; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPERTHERMIA; HYPOTENSION; ISOLATED LIMB PERFUSION; LIMB PERFUSION; LIMB SALVAGE; LOW DRUG DOSE; MOLECULAR IMAGING; MORBIDITY; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; SARCOMA; SURVIVAL RATE; TECHNIQUE; TREATMENT RESPONSE; UNITED STATES;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; LIMB SALVAGE; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 49649098965     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.04.006     Document Type: Review

References (91)

1. Klopp C., Alford T.C., Bateman J., et al. Fractionated intra-arterial cancer chemotherapy with methyl bis-amine hydrochloride; a preliminary report. Ann Surg 132 (1950) 811-832
2. Creech O.J., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer. Regional perfusion utilizing an extracorporeal circuit. Ann Surg 148 (1958) 616-632
3. Creech O.J., Ryan R., and Krementz A. Treatment of malignant melanoma by isolated perfusion technique. JAMA 169 (1959) 339-343
4. Krementz E.T., Carter R.D., Sutherland C.M., et al. Regional chemotherapy for melanoma: a 35 year experience. Ann Surg 220 (1994) 520-535
5. Lebrun J., and Smets W. Regional perfusion by extracorporeal circulation. Surgical technic permitting the administration of anti-cancer chemotherapeutic agents in massive doses. Acta Chir Belg 60 (1961) 368-405
6. Cavaliere R., Ciocatto E.C., Giovanella B.C., et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 20 (1967) 1351-1381
7. Stehlin Jr. J.S., Giovanella B.C., de Ipolyi P.D., et al. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 140 (1975) 339-348
8. Dahl O., and Mella O. Hyperthermia and chemotherapeutic agents. In: Field S.B., and Hand J.W. (Eds). An introduction to the practical aspects of clinical hyperthermia (1990), Taylor & Francis, London 108-142
9. Fontijne W.P., Mook P.H., Schraffordt Koops H., et al. Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. A clinical study. Cancer 55 (1985) 1455-1461
10. Daryanani D., Komdeur R., Ter Veen J., et al. Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 8 (2001) 566-572
11. van Ginkel R.J., Limburg P.C., Piers D.A., et al. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 9 (2002) 355-363
12. Wieberdink J., Benckhuysen C., Braat R.P., et al. Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18 (1992) 905-910
13. Hoekstra H.J., Schraffordt Koops H., Molenaar W.M., et al. Results of isolated regional perfusion in the treatment of malignant soft tissue tumours of the extremities. Cancer 60 (1987) 1703-1707
14. Klaase J.M., Kroon B.B.R., Benckhuijsen C., et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumours of the extremities. Cancer 64 (1989) 616-621
15. Krementz E.T., Carter R.D., Sutherland C.M., et al. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 185 (1977) 555-564
16. Muchmore J.H., Carter R.D., and Krementz E.T. Regional perfusion for malignant melanoma and soft tissue sarcoma: a review. Cancer Invest 3 (1985) 129-143
17. Pommier R.F., Moseley H.S., Cohen J., et al. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg 155 (1988) 667-671
18. Daryanani D., de Vries E.G., Guchelaar H.J., et al. Hyperthermic isolated regional perfusion of the limb with carboplatin. Eur J Surg Oncol 26 (2000) 792-797
19. van Ginkel R.J., Schraffordt Koops H., de Vries E.G., et al. Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone. Eur J Surg Oncol 22 (1996) 528-531
20. Rosenberg S.A., Tepper J., Glatstein E., et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196 (1982) 305-315
21. Eilber F.C., Rosen G., Eckardt J., et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 19 (2001) 3203-3209
22. Nijhuis P.H., Pras E., Sleijfer D.T., et al. Long-term results of preoperative intra-arterial doxorubicin combined with neoadjuvant radiotherapy, followed by extensive surgical resection for locally advanced soft tissue sarcomas of the extremities. Radiother Oncol 51 (1999) 15-19
23. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10 (1992) 52-60
24. Eggermont A.M., Schraffordt Koops H., Lienard D., et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14 (1996) 2653-2665
25. Eggermont A.M., Schraffordt Koops H., Klausner J.M., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224 (1996) 756-764
26. Eggermont A.M., Schraffordt Koops H., Klausner J.M., et al. Limb salvage by isolated perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: result of 270 perfusions in 247 patients. Journal of Clinical Oncology; Proceedings of the American Society of Clinical Oncology 11 (1999) 497
27. Guchelaar H.J., Hoekstra H.J., de Vries E.G., et al. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. Br J Cancer 65 (1992) 898-902 Eur J Surg Oncol 1996;22:528-31
28. Zwaveling J.H., Maring J.K., Clarke F.L., et al. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Crit Care Med 24 (1996) 765-770
29. Hohenberger P., Finke L.H., and Schlag P.M. Intracompartmental pressure during hyperthermic isolated limb perfusion for melanoma and sarcoma. Eur J Surg Oncol 22 (1996) 147-151
30. Schraffordt Koops H. Prevention of neural and muscular lesions during hyperthermic regional perfusion. Surg Gynecol Obstet 135 (1972) 401-403
31. Grunhagen D.J., de Wilt J.H., van Geel A.N., et al. TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 31 (2005) 1011-1019
32. Seynhaeve A.L., Eggermont A.M., and Hagen T.L. TNF and manipulation of the tumor cell stromal interface: "ways to make chemotherapy effective.". Front Biosci 13 (2008) 3034-3045
33. de Wilt J.H., Manusama E.R., van Tiel S.T., et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 80 (1999) 161-166
34. de Wilt J.H., ten Hagen T.L., de Boeck G., et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82 (2000) 1000-1003
35. Fraker D.L., Alexander H.R., Andrich M., et al. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 14 (1996) 479-489
36. Hill S., Fawcett W.J., Sheldon J., et al. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 80 (1993) 995-997
37. Bonvalot S., Laplanche A., Lejeune F., et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?. Ann Oncol 16 (2005) 1061-1068
38. Rossi C.R., Mocellin S., Pilati P., et al. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol 12 (2005) 398-405
39. Di Filippo F., Anza M., Garinei R., et al. Liposomal doxorubicin with and without TNFα in the perfusional treatment of advanced soft tissue limb sarcoma: preliminary results. In Vivo 20 (2006) 735-738
40. Grunhagen D.J., Brunstein F., Graveland W.J., et al. Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol 12 (2005) 473-479
41. Lev-Chelouche D., Abu-Abeid S., Merimsky O., et al. Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma. Arch Surg 134 (1999) 177-180
42. Lans T.E., de Wilt J.H., van Geel A.N., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma. Ann Surg Oncol 9 (2002) 1004-1009
43. Olieman A.F., Pras E., van Ginkel R.J., et al. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 40 (1998) 807-814
44. van Ginkel R.J., Hoekstra H.J., Eggermont A.M., et al. Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan. Arch Surg 131 (1996) 672-674
45. Lans T.E., Grünhagen D.J., de Wilt J.H., et al. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol 12 (2005) 406-411
46. Weitz J., Antonescu C.R., and Brennan M.F. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 21 14 (2003) 2719-2725
47. Olieman A.F., van Ginkel R.J., Molenaar W.M., et al. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?. Arch Orthop Trauma Surg 118 (1998) 70-74
48. Grunhagen D.J., de Wilt J.H., Graveland W.J., et al. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 106 (2006) 156-162
49. Stehlin Jr. J.S., Giovanella B.C., Gutierrez A.E., et al. 15 years' experience with hyperthermic perfusion for treatment of soft tissue sarcoma and malignant melanoma of the extremities. Front Radiat Ther Oncol 18 (1984) 177-182
50. Lehti P.M., Moseley H.S., Janoff K., et al. Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 162 (1986) 149-152
51. Krementz E.T. Lucy Wortham James lecture. Regional perfusion. Current sophistication, what next?. Cancer 57 (1986) 416-432
52. Di Filippo F., Calabrò A.M., Cavallari A., et al. The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities. World J Surg 12 (1988) 332-339
53. Kettelhack C., Kraus T., Hupp T., et al. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 16 (1990) 370-375
54. Eggermont A.M. Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNF-α in combination with γ-interferon and melphalan. In: Fiers W., and Buurman W.A. (Eds). Tumor necrosis factor: molecular and cellular biology and clinical relevance (1993), Karger Publishers, Basel (Switzerland) 239-243
55. Fletcher W.S., Pommier R.F., Woltering E.A., et al. Pharmacokinetics and results of dose escalation in cisplatin hyperthermic isolation limb perfusion. Ann Surg Oncol 1 (1994) 236-243
56. Rossi C.R., Vecchiato A., Foletto M., et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 73 (1994) 2140-2146
57. Santinami M., Deraco M., Azzarelli A., et al. Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan. Tumori 82 (1996) 579-584
58. Rossi C.R., Foletto M., Alessio S., et al. Limb-sparing treatment for soft tissue sarcomas: influence of prognostic factors. J Surg Oncol 63 (1996) 3-8
59. Gutman M., Inbar M., Lev-Shlush D., et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 79 (1997) 1129-1137
60. Lev-Chelouche D., Abu-Abeid S., Nakache R., et al. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Surgery 126 (1999) 963-967
61. Lev-Chelouche D., Abu-Abeid S., Kollander Y., et al. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. Surg Oncol 70 (1999) 185-189
62. Rossi C.R., Foletto M., Di Filippo F., et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 86 (1999) 1742-1749
63. Lejeune F.J., Pujol N., Liénard D., et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 26 (2000) 669-678
64. Hohenberger P., Kettelhack C., Hermann A., et al. Functional outcome after preoperative isolated limb perfusion with rhTNFalpha/melphalan for high grade extremity sarcoma. Eur J Cancer 37 6 (2001) S34-S35
65. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer 98 (2003) 1483-1490
66. van Etten B., van Geel A.N., de Wilt J.H., et al. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 10 (2003) 32-37
67. Di Filippo F., Garinei R., Anzà M., et al. Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma. J Exp Clin Cancer Res 22 Suppl 4 (2003) 81-87
68. Feig B.W., Ross M.I., and Hunt K.K. A prospective evaluation of isolated limb perfusion with doxorubicin in patients with unresectable extremity sarcomas. [abstract 98]. Ann Surg Oncol 11 Suppl (2004) S80
69. Grunhagen D.J., de Wilt J.H., Verhoef C., et al. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur J Surg Oncol 31 (2005) 912-916
70. Grunhagen D.J., de Wilt J.H., Graveland W.J., et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb threatening soft tissue sarcoma. Cancer 106 (2006) 1776-1784
71. Schlag P.M., and Tunn P.U. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Dtsch Arztebl 104 (2007) 2268-2273
72. van Ginkel R.J., Thijssens K.M., Pras E., et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol 14 (2007) 1499-1506
73. Hoven-Gondrie M.L., Thijssens K.M., Van den Dungen J.J., et al. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol 14 (2007) 2105-2112
74. Hoven-Gondrie M.L., Thijssens K.M.J., Geertzen J.H.B., et al. Isolated limb perfusion and external beam radiotherapy for soft tissue sarcomas of the extremity: long-term effects on normal tissue according to the LENT-SOMA scoring system. Ann Surg Oncol 15 (2008) 1502-1510
75. Vrouenraets B.C., Kroon B.B., Ogilvie A.C., et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 6 (1999) 405-412
76. Vrouenraets B.C., Eggermont A.M., Hart A.A., et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 27 (2001) 390-395
77. Olieman A.F., van Ginkel R.J., Hoekstra H.J., et al. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 4 (1997) 64-69
78. Rüegg C., Yilmaz A., Bieler G., et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4 (1998) 408-414
79. Saleem A., Charnley N., and Price P. Clinical molecular imaging with positron emission tomography. Eur J Cancer 42 (2006) 1720-1727
80. Bastiaannet E., Groen H., Jager P.L., et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30 (2004) 83-101
81. Nieweg O.E., Pruim J., van Ginkel R.J., et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 37 (1996) 257-261
82. Groves A.M., Win T., Haim S.B., et al. Non-[18F]FDG PET in clinical oncology. Lancet Oncol 8 (2007) 822-830
83. van Ginkel R.J., Hoekstra H.J., Pruim J., et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 37 (1996) 984-990
84. van Ginkel R.J., Kole A.C., Nieweg O.E., et al. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. J Nucl Med 40 (1999) 262-267
85. Been L.B., Suurmeijer A.J., Elsinga P.H., et al. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med 48 (2007) 367-372
86. Available at:. http://www.ctos.org Accessed May 25, 2008
87. Thijssens K.M., Hoekstra-Weebers J.E., van Ginkel R.J., et al. Quality of life after hyperthermic isolated limb perfusion for locally advanced extremity soft tissue sarcoma. Ann Surg Oncol 13 (2006) 864-871
88. van Weert E., Hoekstra-Weebers J., Grol B., et al. A multidimensional cancer rehabilitation program for cancer survivors: effectiveness on health-related quality of life. J Psychosom Res 58 (2005) 485-496
89. Thompson J.F., and Kam P.C. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. Surg Oncol 88 (2004) 1-3
90. Brady M.S., Brown K., Patel A., et al. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 13 (2006) 1123-1129
91. Kirsch D.G., Dinulescu D.M., Miller J.B., et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13 (2007) 992-997